Real‐time impact of COVID‐19 pandemic on cutaneous leishmaniasis case finding and strategic planning, preventive interventions, control and epidemiology in a region with a high burden of cutaneous leishmaniasis and COVID‐19: A cross‐sectional descriptive study based on registry data in Ilam‐Iran

Abstract Background and Aims Cutaneous leishmaniasis (CL) is a severe parasitic disease affecting people, mostly in underdeveloped nations. As a zoonotic infection yearly incidence of CL depends on several parameters such as demographic, epidemiological, and environmental factors as well as prevention and control measures. The sudden outbreak of pandemics such as SARS‐Corona‐Virus‐2 pandemic, can probably affect the incidence or reporting of other diseases, especially infectious diseases, in various ways such as pressure on health systems, providing sanitary services and its components, lockdowns and changes in people's living habits. Aim This study aimed to evaluate the COVID‐19 impact on the incidence and other epidemiological aspects as well as control measures of CL in Ilam Province‐Iran. Methods Required data was extracted from the CL registration system in Ilam from 2014 to 2021 to demonstrate the trend of CL incidence before and after COVID‐19 pandemic. Results Based on our results, a declining pattern of CL incidence was observed, accompanied by the advent and intensification of the viral pandemic in Iran and Ilam province. Although, this decreasing pattern was not integral in all areas, and even increase in CL detection was emphasized in some regions. Conclusion It may be inferred that the COVID‐19 pandemic may disrupt treatment programs of CL cases, rodent nest destruction, and fighting vector insects.

[1]  M. Barrett,et al.  Drug resistance in Leishmania: does it really matter? , 2023, Trends in parasitology.

[2]  S. Falahi,et al.  Systematic Review and Meta-analysis of Role of Felids as Intermediate Hosts in the Life Cycle of Neospora caninum Based on Serological Data , 2023, Acta Parasitologica.

[3]  S. Falahi,et al.  Assessment of genetic markers for multilocus sequence typing (MLST) of Fasciola isolates from Iran , 2022, Veterinary medicine and science.

[4]  A. Kenarkoohi,et al.  Immunogenicity of COVID‐19 mRNA vaccines in hemodialysis patients: Systematic review and meta‐analysis , 2022, Health science reports.

[5]  A. Kenarkoohi,et al.  COVID-19 Mass Vaccination and Flu season: Concern for Decreased Public Health Measures and worsening the influenza situation. , 2022, Infectious disorders drug targets.

[6]  A. Abdoli,et al.  Outbreak of cutaneous leishmaniasis before and during the COVID-19 pandemic in Jahrom, an endemic region in the southwest of Iran , 2022, Emerging microbes & infections.

[7]  A. Kenarkoohi,et al.  Sufficient Sleep, Time of Vaccination, and Vaccine Efficacy: A Systematic Review of the Current Evidence and a Proposal for COVID-19 Vaccination , 2022, The Yale journal of biology and medicine.

[8]  A. Kenarkoohi,et al.  COVID-19 vaccination, Peltzman Effect and possible increase in high-risk behaviors: a growing concern on risk compensation and reduced compliance to Public Health protective Measures after vaccines rollout. , 2022, Infectious disorders drug targets.

[9]  M. Shirzadi,et al.  Fifty years of struggle to control cutaneous leishmaniasis in the highest endemic county in Iran: A longitudinal observation inferred with interrupted time series model , 2022, PLoS neglected tropical diseases.

[10]  F. Najafi,et al.  Demographics, clinical characteristics, and outcomes of 27,256 hospitalized COVID-19 patients in Kermanshah Province, Iran: a retrospective one-year cohort study , 2022, BMC Infectious Diseases.

[11]  A. Kenarkoohi,et al.  An update review on complicated mechanisms of COVID-19 pathogenesis and therapy: direct viral damage, renin-angiotensin system dysregulation, immune system derangements, and endothelial dysfunction. , 2022, Infectious disorders drug targets.

[12]  A. Kenarkoohi,et al.  Interleukin‐29 profiles in COVID‐19 patients: Survival is associated with IL‐29 levels , 2022, Health science reports.

[13]  A. Kenarkoohi,et al.  Changes in Physiological Levels of Cortisol and Adrenocorticotropic Hormone upon Hospitalization Can Predict SARS-CoV-2 Mortality: A Cohort Study , 2022, International journal of endocrinology.

[14]  M. Gramiccia,et al.  Surveillance of leishmaniasis cases from 15 European centres, 2014 to 2019: a retrospective analysis , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  S. Rodríguez-Couto,et al.  Socio-Environmental Determinants and Human Health Exposures in Arid and Semi-Arid Zones of Iran—Narrative Review , 2022, Environmental health insights.

[16]  Özlem Ulusan Bağcı Impact of the COVID-19 Duration on Neglected Parasitic Diseases. , 2021, Turkiye parazitolojii dergisi.

[17]  A. Kenarkoohi,et al.  Host factors and vaccine efficacy: Implications for COVID‐19 vaccines , 2021, Journal of medical virology.

[18]  P. Saberian,et al.  Changes in COVID-19 IgM and IgG antibodies in emergency medical technicians (EMTs) , 2021, The American Journal of Emergency Medicine.

[19]  A. Azman,et al.  Towards global control of parasitic diseases in the Covid-19 era: One Health and the future of multisectoral global health governance , 2021, Advances in Parasitology.

[20]  P. Bonan,et al.  COVID-19 Pandemic Causes Increased Clinic Visits with Diagnosis of Tegumentary Leishmaniasis in Brazil in 2020 , 2021, International Journal of Infectious Diseases.

[21]  M. Azage,et al.  Effect of the COVID-19 Pandemic Preparation and Response on Essential Health Services in Primary and Tertiary Healthcare Settings of Amhara Region, Ethiopia , 2021, The American journal of tropical medicine and hygiene.

[22]  S. Falahi,et al.  Outcome evaluation of COVID-19 infected patients by disease symptoms: a cross-sectional study in Ilam Province, Iran , 2021, BMC Infectious Diseases.

[23]  R. Cantón,et al.  COVID-19: Impact on prescribing and antimicrobial resistance , 2021, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[24]  A. Kenarkoohi,et al.  Environmental Surface Contamination with SARS-CoV-2: Toilets as the Most Contaminated Surfaces in COVID-19 Referral Hospital , 2021, Hospital topics.

[25]  A. Kenarkoohi,et al.  COVID-19-associated opportunistic infections: a snapshot on the current reports , 2021, Clinical and Experimental Medicine.

[26]  T. Dzieciątkowski,et al.  The New Status of Parasitic Diseases in the COVID-19 Pandemic—Risk Factors or Protective Agents? , 2021, Journal of clinical medicine.

[27]  A. Kenarkoohi,et al.  Prevalence and clinical presentation of COVID-19 infection in hemodialysis patients , 2021, Journal of Nephropathology.

[28]  D. C. Miguel,et al.  The impact of COVID-19 on neglected parasitic diseases: what to expect? , 2021, Trends in Parasitology.

[29]  S. Fauziyah,et al.  How should Indonesia consider its neglected tropical diseases in the COVID-19 era? Hopes and challenges (Review) , 2021, Biomedical reports.

[30]  V. Ziaee,et al.  Clinical Misdiagnosis of COVID-19 Infection with Confusing Clinical Course , 2021, Case reports in infectious diseases.

[31]  A. Kenarkoohi,et al.  Claims and reasons about mild COVID-19 in children , 2021, New Microbes and New Infections.

[32]  F. Bahrami,et al.  Cutaneous leishmaniasis in Iran: A systematic review and meta-analysis. , 2021, Microbial pathogenesis.

[33]  M. Saraei,et al.  Cutaneous leishmaniasis as an increasing threat for Iranian travellers attending religious ceremonies. , 2021, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[34]  A. Rezaie,et al.  The potential therapeutic effect of adipose-derived mesenchymal stem cells in the treatment of cutaneous leishmaniasis caused by L. major in BALB/c mice. , 2021, Experimental parasitology.

[35]  K. Ghadiri,et al.  Prevalence of human visceral leishmaniasis in Iran: A systematic review and meta-analysis. , 2020, Comparative immunology, microbiology and infectious diseases.

[36]  Mirza Ali Mofazzal Jahromi,et al.  Infections, inflammation, and risk of neuropsychiatric disorders: the neglected role of “co-infection” , 2020, Heliyon.

[37]  A. Abdoli,et al.  Iran, sanctions, and the COVID-19 crisis , 2020, Journal of medical economics.

[38]  L. Coffeng,et al.  Modelling the impact of COVID-19-related programme interruptions on visceral leishmaniasis in India , 2020, medRxiv.

[39]  Shahab Falahi,et al.  Transmission routes for SARS-CoV-2 infection: review of evidence , 2020, New Microbes and New Infections.

[40]  Michael S. Deiner,et al.  Predicted Impact of COVID-19 on Neglected Tropical Disease Programs and the Opportunity for Innovation , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  M. B. Eslaminejad,et al.  Therapeutic effects of Mesenchymal Stem Cells on Cutaneous Leishmaniasis Lesions caused by Leishmania major. , 2020, Journal of global antimicrobial resistance.

[42]  S. Mohammadi,et al.  The prevalence of human bocavirus in <2-year-old children with acute bronchiolitis , 2020, New microbes and new infections.

[43]  A. Picado,et al.  Diagnosis of neglected tropical diseases during and after the COVID-19 pandemic , 2020, PLoS neglected tropical diseases.

[44]  F. Karaca,et al.  Impact of COVID-19 Event on the Air Quality in Iran , 2020 .

[45]  M. Soleimani,et al.  HSV-TK Expressing Mesenchymal Stem Cells Exert Inhibitory Effect on Cervical Cancer Model , 2020, International journal of molecular and cellular medicine.

[46]  A. Kenarkoohi,et al.  Report of 5 nurses infecting COVID-19 during patient care: case Series , 2020, New Microbes and New Infections.

[47]  A. Kenarkoohi,et al.  The COVID-19 pandemic, psychological stress during pregnancy, and risk of neurodevelopmental disorders in offspring: a neglected consequence , 2020, Journal of psychosomatic obstetrics and gynaecology.

[48]  S. Soudi,et al.  Repeated intravenous injection of adipose tissue derived mesenchymal stem cells enhances Th1 immune responses in Leishmania major-infected BALB/c mice. , 2019, Immunology letters.

[49]  D. Sandoval,et al.  Autochthonous cutaneous leishmaniasis in urban domestic animals (Felis catus / Canis lupus familiaris) from central-western Venezuela. , 2019, Acta tropica.

[50]  N. Nazari,et al.  Cutaneous leishmaniasis in Qasr-e Shirin, a border area in the west of Iran , 2018, Veterinary world.

[51]  Mohammad Reza Aflatoonian,et al.  A newly emerged focus of zoonotic cutaneous leishmaniasis in South-western Iran. , 2018, Microbial pathogenesis.

[52]  J. Abdi,et al.  Seroprevalence of Toxocara in Children from Urban and Rural Areas of Ilam Province, West Iran , 2018, Osong public health and research perspectives.

[53]  M. Booth Climate Change and the Neglected Tropical Diseases , 2018, Advances in Parasitology.

[54]  A. Khamesipour,et al.  Genetic Diversity and Phylogenetic Analysis of the Iranian Leishmania Parasites Based on HSP70 Gene PCR-RFLP and Sequence Analysis , 2017, The Korean journal of parasitology.

[55]  A. Foroumadi,et al.  Synthesis and Leishmanicidal Activity of 1-[5-(5-Nitrofuran-2-yl)-1, 3, 4-Thiadiazole-2-yl]-4-BenzoylePiperazines , 2017, Iranian journal of pharmaceutical research : IJPR.

[56]  A. Campos-Neto,et al.  CD271+ Mesenchymal Stem Cells as a Possible Infectious Niche for Leishmania infantum , 2016, PloS one.

[57]  M. Gouya,et al.  Cutaneous leishmaniasis in Iran: Results from an epidemiological study in urban and rural provinces , 2016 .

[58]  J. Abdi,et al.  Identification and determination of the prevalence of Toxoplasma gondii in patients with chronic renal failure by ELISA and PCR , 2016 .

[59]  M. Shirzadi,et al.  Epidemiological status of leishmaniasis in the Islamic Republic of Iran, 1983-2012. , 2015, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[60]  M. Soleimani,et al.  Efficient Lentiviral Transduction of Adipose Tissue-Derived Mouse Mesenchymal Stem Cells and Assessment of Their Penetration in Female Mice Cervical Tumor Model , 2014, Iranian journal of cancer prevention.

[61]  B. Sarkari,et al.  Knowledge, attitude, and practices related to cutaneous leishmaniasis in an endemic focus of cutaneous leishmaniasis, Southern Iran. , 2014, Asian Pacific journal of tropical biomedicine.

[62]  Dylan B. George,et al.  Global distribution maps of the leishmaniases , 2014, eLife.

[63]  R. López-Vélez,et al.  Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study. , 2014, Travel medicine and infectious disease.

[64]  M. Taran,et al.  Larvicidal Effects of Essential Oil and Methanolic Extract of Hymenocarter longiflorus (Lamiaceae ) Against Echinococcus granulosus , 2013 .

[65]  S. Falahi,et al.  Phylogenetic Analysis of Torque Teno Virus in Hepatitis C Virus Infected Patients in Shiraz , 2012, Hepatitis monthly.

[66]  M. Nilforoushzadeh,et al.  The knowledge, attitude, and prevention practices of students regarding cutaneous leishmaniasis in the hyperendemic region of the Shahid Babaie Airbase. , 2012, Vector borne and zoonotic diseases.

[67]  Hossein Riahi Madvar,et al.  Prediction of hepatitis B virus lamivudine resistance based on YMDD sequence data using an artificial neural network model , 2011 .

[68]  A. Khorsandi,et al.  EPIDEMIOLOGY OF CUTANEOUS LEISHMANIASIS IN DAMGHAN DISTRICT , 2010 .

[69]  M. Bandehpour,et al.  Serological Evaluation of EgAgB16 kDa, a Recombinant Antigen from Echinococcus granulosus for Diagnosis of Human Hydatidosis , 2010, Iranian journal of parasitology.

[70]  P J Hotez,et al.  Mass Drug Administration and Integrated Control for the World's High‐Prevalence Neglected Tropical Diseases , 2009, Clinical pharmacology and therapeutics.

[71]  R. Mirnejad,et al.  Epidemic Assessment of Bacterial Agents in Osteomyelitis and Their Antibiotic Resistance Pattern Determination , 2008 .

[72]  H. Najmabadi,et al.  Fourteen-Year Experience of Prenatal Diagnosis of Thalassemia in Iran , 2006, Public Health Genomics.

[73]  J. Berman,et al.  Advances in leishmaniasis , 2005, The Lancet.

[74]  A. Akhavan,et al.  Rodent control operations against zoonotic cutaneous leishmaniasis in rural Iran , 2005, Annals of Saudi medicine.

[75]  P. Desjeux Leishmaniasis: current situation and new perspectives. , 2004, Comparative immunology, microbiology and infectious diseases.

[76]  F. Modabber,et al.  Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan , 2000, The Lancet.

[77]  A. Khamesipour,et al.  Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran , 1998, The Lancet.

[78]  S. Croft,et al.  Liposomal amphotericin B in drug-resistant visceral leishmaniasis , 1991, The Lancet.

[79]  A. Kenarkoohi,et al.  CLINICAL FEATURES OF NOVEL CORONAVIRUS 2019-INFECTED CASES WITH PRE-EXISTING CARDIOVASCULAR DISEASE, DISAGGREGATED BY GENDER , 2021 .

[80]  A. Berg,et al.  Present and future Köppen-Geiger climate classification maps at 1-km resolution. , 2018, Scientific data.

[81]  LEISHMANIASIS Epidemiological Report of the Americas , 2018 .

[82]  S. Brooker,et al.  Cutaneous leishmaniasis. , 2007, The Lancet. Infectious diseases.